Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(d) On June 14, 2022, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”)
elected Mr. Deepak L. Bhatt, M.D., M.P.H., to serve as a member of the Board, effective June 14, 2022. The size of the Board was increased to eleven, effective June 14, 2022, in connection with the
election of Dr. Bhatt.
Mr. Deepak L. Bhatt, M.D., M.P.H., is 54 years old and has more than 20 years of experience in
acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has served as the principal or co-principal investigator for cardiovascular clinical
trials focused on interventional cardiology, anti-thrombotic therapy, lipid-lowering therapy, heart failure, obesity, and diabetes, among other areas.
Since 2013, Dr. Bhatt has served as the Executive Director of Interventional Cardiovascular programs at Brigham and Women’s
Hospital. He is also a Professor of Medicine at Harvard Medical School.
Prior to his current position, Dr. Bhatt served as
Chief of Cardiology at VA Boston Healthcare from 2008-2013. From 2001-2008, he held a number of roles of increasing responsibility at the Cleveland Clinic in Cleveland, Ohio. In addition to being an attending physician, he served as an Associate
Director of the Cleveland Clinic Cardiovascular Coordinating Center, Director of the Interventional Cardiology Fellowship, as well as the Associate Director of the Cardiovascular Medicine Fellowship. Dr. Bhatt received his undergraduate degree, a
Bachelor of Science, from Massachusetts Institute of Technology. He received his Medical Degree from Cornell University and a Master’s in Public Health from the Harvard School of Public Health. He completed his Internship and Residency training in
Internal Medicine at the Hospital of the University of Pennsylvania and was a fellow in Interventional Cardiology and Cerebral and Peripheral
Vascular Intervention at the Cleveland Clinic.
The Board has determined that Dr. Bhatt is independent under the New York Stock Exchange Listing Standards and the independence standards adopted by
the Board. Dr. Bhatt will serve as a member of the Science and Technology Committee, effective June 14, 2022.
There are no arrangements or understandings between Dr. Bhatt and any other persons pursuant to which he was selected as a director. There are no
related party transactions between the Company and Dr. Bhatt.
Dr. Bhatt will receive compensation for his service on the Board in accordance with the Company’s standard compensatory arrangement for non-employee
directors, including an annual retainer of $105,000 and an annual award of deferred share units valued at $200,000 on the date of grant.
A copy of the press release announcing the election of Dr. Bhatt is attached to this report as Exhibit 99.1.